Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at firstname.lastname@example.org.
Articles by Eric Palmer
Sanofi, which bought controlling interest in Dubai's Globalpharma in June, will kick off production there with generics of 6 of its drugs. Sanofi is now managing the facility.
A Turkish man who admitted to smuggling counterfeit cancer drugs to the U.S. labeled as gifts or documents has been sentenced to 27 months in federal prison.
Novo Nordisk in August bought a plant in New Hampshire that Japan's Olympus Biologics was giving up. Now it is looking for people to help operate it.
Eli Lilly has published a how-to paper about its ambitious technology transfer program to help China, India, Russia and South Africa produce two drugs to treat multidrug-resistant tuberculosis. The bottom line is that the undertaking was harder than expected, and while it did not fully achieve all of its goals, it was worth doing.
Genentech CEO Ian Clark is again being publicly chastised for his company's decision to move three of its best-selling cancer drugs to specialty distributors. Groups representing more than 5,000 hospitals say, besides higher costs, the move is as likely to encourage counterfeiting as to deter it.
The vaccinemaker Serum Institute of India, which jumped into the biosimilars race in July, is expanding its manufacturing network both in India and the Netherlands. The company says it will invest about $163 million for a new facility in its home country.
Hikma Pharmaceuticals got a closeout notice in March for a warning letter that had been hanging over its West-Ward plant in New Jersey. But at nearly the same time, inspectors were looking over a Hikma facility in Portugal, and the Jordan-based company says the FDA has now issued a warning letter for its sterile injectables plant there.
Despite FDA bans on four Ranbaxy Laboratories plants in India, the drugmaker managed to realize a profit in the last quarter as its plant in New Jersey was able to come through for it.
For $275 million, Australia's CSL is buying from Novartis a network of vaccine manufacturing facilities, as well as a portfolio of products.
Fujifilm said Monday that its Fujifilm Diosynth Biotechnologies subsidiary is buying a 49% interest in Kalon from its owners, which includes the Texas A&M University System where Kalon was founded in 2011. Terms of the deal, which is expected to close in the next few months, were not provided, but Fujifilm said it may buy the rest of Kalon, assuming certain milestones are hit.